Public Release: 

Test could predict whether breast cancer will spread to the brain

Institute of Cancer Research

Women with particularly aggressive forms of breast cancer could be identified by a test that predicts whether the disease is likely to spread to the brain.

An analysis of almost 4,000 patients with breast cancer found that testing for high activity in a particular gene called alpha beta (αB)-crystallin could pick out women who were at greater risk of developing secondary brain tumors compared to women who tested negative.

A team including scientists at The Institute of Cancer Research, London, found that women whose breast cancer had begun to spread and who tested positive in the αB-crystallin test were three times more likely to have disease that spread to the brain than those who tested negative.

The international research effort also included researchers at the University of North Carolina at Chapel Hill, the University of Wisconsin-Madison and the British Columbia Cancer Agency, Canada.

The study was published today in the journal npj Breast Cancer and funded by the Breast Cancer Research Foundation, the US National Cancer Institute, Cancer Research UK and the Canadian Breast Cancer Foundation.

Women can live for years with breast cancer that has begun to spread around the body -- but the exception is spread to the brain, which usually indicates a woman is in her last few months of life.

In the study, the researchers analysed 969 breast cancer tumors which ultimately spread, or metastasised, to new sites in the body, from a database of almost 4,000 breast cancers from the British Columbia Cancer Agency. 141 had spread first to the brain.

Some 127 scored positive for αB-crystallin, and 842 negative -- with those testing positive three times more likely to have spread first to the brain.

In a further analysis of all 4,000 cases, αB-crystallin was also linked with a significantly higher risk of death -- with 36 per cent of women with αB-crystallin positive cancer, compared to 25 per cent with αB-crystallin negative, dying within ten years of diagnosis.

Study co-leader Dr Maggie Cheang, Senior Staff Scientist at The Institute of Cancer Research, London, said:

"Spread of breast cancer to the brain is unfortunately very dangerous, and usually leads to death within months. It's important to find new ways to identify women who are most at risk of their cancer spreading to the brain, so that doctors can work out which women might need more intensive or new treatments to try to keep their cancer at bay for longer.

"Our study linked a positive score in this test with quicker spread to the brain, and importantly showed the factor we were measuring is providing information on patient outcome independently of other biomarkers already measured in the clinic.

"The test needs further development before it will be ready for routine clinical use, but ultimately the first use of this type of test could be to identify opportunities for women with advanced specific types of breast cancer -- such as triple negative -- to enter clinical trials of new treatments."

Canada study leader Professor Torsten Nielsen, Pathologist at the British Columbia Cancer Agency, said:

"It has taken us years to assemble the clinical outcome database and tissue samples, generate the immunohistochemical biomarkers, gene expression profiles and analyse the data for this study -- and we were delighted to find a definite link between alpha beta crystallin and breast cancer progression, which we hope will ultimately improve clinical outcomes.

"Our study also definitely demonstrates the importance of team science to deliver a study involving international collaborations".

###

Notes to editors

For more information please contact
Henry French
020 7153 5282
henry.french@icr.ac.uk.

For enquiries out of hours, please call 07595 963613.

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.